Pegcetacoplan

Complement Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Pegcetacoplan is a drug in the Complement Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Complement Inhibitors. DrugCentral lists 1 molecular target, including C3. Recorded indications include Geographic atrophy secondary to age-related macular degeneration and Paroxysmal nocturnal hemoglobinuria.

• Drug class: Complement Inhibitor.
• Mechanism of action: Complement Inhibitors.
• Molecular targets: C3 (1 listed in DrugCentral).
• Indications: Geographic atrophy secondary to age-related macular degeneration and Paroxysmal nocturnal hemoglobinuria.
• ATC code: L04AJ03 (Complement inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Geographic atrophy secondary to age-related macular degeneration
• Paroxysmal nocturnal hemoglobinuria

Contraindications (4)

• Ocular or periocular infection
• Unresolved serious infection caused by Haemophilus influenzae
• Unresolved serious infection caused by Neisseria meningitidis
• Uveitis

Mechanism & targets

• Mechanism of action (MoA): Complement Inhibitors
• Established pharmacologic class: Complement Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Complement C3	C3	inhibitor	IC50 6.60

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2023-03-27	PMDA	—	Swedish Orphan Biovitrum Japan Co., Ltd.
2021-12-13	EMA	—	SWEDISH ORPHAN BIOVITRUM AB (PUBL)	Yes
2021-05-14	FDA	—	APELLIS PHARMACEUTICALS INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L04AJ03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors
S01XA31	SENSORY ORGANS › OPHTHALMOLOGICALS › OTHER OPHTHALMOLOGICALS › Other ophthalmologicals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Breakthrough haemolysis	526.9
Choroidal neovascularisation	418.2
Vitritis	401.5
Vitreous floaters	397.6
Neovascular age-related macular degeneration	335.2
Haemolysis	286.4
Uveitis	274.3
Eye complication associated with device	234.4
Eye inflammation	229.6
Retinal vasculitis	226.4
Visual impairment	223.8
Retinal haemorrhage	215.5

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 2019171-69-6
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pegcetacoplan used for?

DrugCentral lists the following indications for Pegcetacoplan: Geographic atrophy secondary to age-related macular degeneration and Paroxysmal nocturnal hemoglobinuria.

How does Pegcetacoplan work?

Pegcetacoplan is classified as Complement Inhibitors; its molecular targets in DrugCentral include C3 (inhibitor).

When was Pegcetacoplan first approved?

Pegcetacoplan was first approved by the FDA in 2021.

What drug class does Pegcetacoplan belong to?

Pegcetacoplan is in the Complement Inhibitor class.

Sources

• DrugCentral drug card 5457 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4298211 — compound record and bioactivity
• DrugBank DB16694 — drug record
• FDA UNII TO3JYR3BOU — substance identity
• DailyMed: FDA labels for Pegcetacoplan — current prescribing information (label search)
• UniProt P01024 (C3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.